Editor

8391 POSTS
0 COMMENTS

Pancreatic Most cancers on the Rise Amongst Youthful Adults

Following the Oct. 14, 2025 dying of R&B singer D’Angelo from pancreatic most cancers on the age of 51, CURE spoke with...

Masking Each FDA Oncology Approval From October 2025

In October 2025, the U.S. Meals and Drug Administration (FDA) granted approval to a number of new most cancers therapies and supportive...

Why ‘There may be Hope’ For Sufferers With Pancreatic Most cancers

Coinciding with the commentary of Pancreatic Most cancers Consciousness Month in November, CURE sat down for an interview with Dr. Rosario Ligresti...

Strolling By way of It All: Staying Energetic With Most cancers and Knee Surgical procedure

I've been a walker lengthy earlier than my prognosis of small lymphocytic lymphoma sixteen years in the past. After that prognosis —...

FDA Approves Stoboclo and Osenvelt as Biosimilars for Some Cancers

The U.S. Meals and Drug Administration (FDA) has authorised two new biosimilars as reference merchandise for Prolia (denosumab) and XGEVA® (denosumab): Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo),...

Editor

8391 POSTS
0 COMMENTS
spot_img